Merck’s Keytruda prolong life in lung cancer study

According to report, Merck & Co's
approved Keytruda lung cancer
treatment is said to provided superior
overall survival to chemotherapy.

This is confirmed
in a late-stage study of patients
with advanced disease whose
tumors produce a protein called
PD-L1 associated with increased
risk of the disease.

Comments

Popular posts from this blog

Pfizer and Merck KGaA suffered another setback with immuno-oncology med Bavencio

Alzheimer’s disease reversed in mice, offering hope for humans

The U.S. Food and Drug Administration granted approval for expanded use of Imfinzi to treat non-small cell lung cancer (NSCLC) patients